JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme

Completed

Phase 3 Results

Summary of Purpose

Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 21 January 2014.

1 Apr 2006 28 Mar 2006 1 Mar 2009 Unavailable 1 Jan 2014 16 Feb 2010
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Purpose: Prevention
  • Intervention: Parallel Assignment

Contacts

  • Yasuhisa Urano Nippon Boehringer Ingelheim Co., Ltd.

    URANOY@kaw.boehringer-ingelheim.com